DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Q2 Results on October 26: Paytm, Mankind Pharma, Tata Consumer Products among 90 companies in the list

Zee Business 3 hrs ago·23 Oct 2026, 1:37 pm

Mankind Pharma

Investors are preparing for a busy earnings season as Mankind Pharma is set to announce its second-quarter results on October 26. This report will detail the company's financial performance over the past three months, including key metrics like revenue and profit.

The outcome of this announcement is significant for shareholders, as it provides a clear picture of the company's current health and future growth trajectory. Investors will closely analyze the figures to gauge the company's operational efficiency and market position.

Moving forward, market participants will focus on management commentary regarding future outlook and any strategic initiatives. This information will be crucial in determining the stock's short-term and long-term investment potential.